Cervical Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2017

Cervical Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2017


  • Products Id :- GDME0393EPD
  • |
  • Pages: 102
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cervical Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2017

Summary

GlobalData's Medical Devices sector report, "Cervical Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2017" provides an overview of Cervical Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cervical Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Cervical Cancer Diagnostic Tests under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Cervical Cancer Diagnostic Tests and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoing trials specific to pipeline products

Recent developments in the segment / industry

Reasons to buy

The report enables you to-

Formulate significant competitor information, analysis, and insights to improve R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of Cervical Cancer Diagnostic Tests under development

Develop market-entry and market expansion strategies

Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

In-depth analysis of the product's current stage of development, territory and estimated launch date



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Cervical Cancer Diagnostic Tests Overview 8

3 Products under Development 9

3.1 Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 9

3.2 Cervical Cancer Diagnostic Tests-Pipeline Products by Territory 10

3.3 Cervical Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 11

3.4 Cervical Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 12

3.5 Cervical Cancer Diagnostic Tests-Ongoing Clinical Trials 13

4 Cervical Cancer Diagnostic Tests-Pipeline Products under Development by Companies 14

4.1 Cervical Cancer Diagnostic Tests Companies-Pipeline Products by Stage of Development 14

4.2 Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 16

5 Cervical Cancer Diagnostic Tests Companies and Product Overview 17

5.1 Alere Inc Company Overview 17

5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 17

5.2 Becton Dickinson and Co Company Overview 18

5.2.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 18

5.3 Bio Techne Corp Company Overview 20

5.3.1 Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview 20

5.4 BioAffinity Technologies, Inc. Company Overview 21

5.4.1 BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 BioMark Diagnostics Inc. Company Overview 22

5.5.1 BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 BioMark Technologies Inc Company Overview 23

5.6.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 23

5.7 Cepheid Company Overview 24

5.7.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 24

5.8 China Sky One Medical Inc Company Overview 25

5.8.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 25

5.9 Cytosystems Ltd Company Overview 26

5.9.1 Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

5.10 Enzo Life Sciences Inc Company Overview 27

5.10.1 Enzo Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.11 Genisphere LLC Company Overview 28

5.11.1 Genisphere LLC Pipeline Products & Ongoing Clinical Trials Overview 28

5.12 Genomic Vision Company Overview 29

5.12.1 Genomic Vision Pipeline Products & Ongoing Clinical Trials Overview 29

5.13 GenomicTree Inc Company Overview 32

5.13.1 GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview 32

5.14 Golden Valley Development, Inc. Company Overview 34

5.14.1 Golden Valley Development, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34

5.15 GRANT Life Sciences, Inc. Company Overview 35

5.15.1 GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35

5.16 Louisville Bioscience, Inc. Company Overview 36

5.16.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 36

5.17 MDNA Life Sciences Inc Company Overview 37

5.17.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 37

5.18 MDxHealth SA Company Overview 38

5.18.1 MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 38

5.19 Milagen Inc Company Overview 39

5.19.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 39

5.20 Newcastle University Company Overview 40

5.20.1 Newcastle University Pipeline Products & Ongoing Clinical Trials Overview 40

5.21 Olympia Diagnostics, Inc Company Overview 41

5.21.1 Olympia Diagnostics, Inc Pipeline Products & Ongoing Clinical Trials Overview 41

5.22 Oncgnostics GmbH Company Overview 43

5.22.1 Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 43

5.23 ONCOVEDA Cancer Research Center Company Overview 45

5.23.1 ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 45

5.24 Orion Genomics LLC Company Overview 46

5.24.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 46

5.25 Precision Biologics Inc Company Overview 47

5.25.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 47

5.26 Preciva Incorporated Company Overview 48

5.26.1 Preciva Incorporated Pipeline Products & Ongoing Clinical Trials Overview 48

5.27 Roche Diagnostics International Ltd Company Overview 49

5.27.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 49

5.28 University of Manchester Company Overview 50

5.28.1 University of Manchester Pipeline Products & Ongoing Clinical Trials Overview 50

5.29 US Biomarkers Inc Company Overview 51

5.29.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 51

5.30 Vanderbilt University Company Overview 52

5.30.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 52

5.31 XEPTAGEN SpA Company Overview 53

5.31.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 53

6 Cervical Cancer Diagnostic Tests-Recent Developments 54

6.1 Jul 25, 2017: Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook 54

6.2 Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation 54

6.3 Jun 09, 2017: R-way achievement in The 16th IFCPC Congress 54

6.4 Jun 06, 2017: BD Releases 2016 Sustainability Report 55

6.5 Jun 02, 2017: Cancer Genetics to Present at the 7th Annual LD Micro Invitational 55

6.6 May 17, 2017: Mel-Mont Medical announces the development of Mia by XytoTest, a self-collected cervical sample that seeks to eradicate cervical cancer 56

6.7 May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability 56

6.8 May 10, 2017: Genomic Vision Announces Promising Preliminary Results for Its Clinical Study in Cervical Cancer Detection in the Czech Republic 58

6.9 May 10, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations 59

6.10 May 09, 2017: Genomic Vision: Financial Information at March 31, 2017 59

6.11 May 08, 2017: MDxHealth Trading Update: January to April 2017 60

6.12 May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter 61

6.13 Apr 28, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations 63

6.14 Apr 27, 2017: MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer 64

6.15 Apr 23, 2017: BD Announces Appointment Of Tom Polen As President 64

6.16 Apr 20, 2017: Quest Diagnostics Reports First Quarter 2017 Financial Results, Raises 2017 Financial Outlook 65

6.17 Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management 65

6.18 Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update 65

6.19 Mar 22, 2017: Vigilant Biosciences Announces Multiple Poster Presentations in Support of OncAlert Oral Cancer and OncAlert Labs Product Lines 67

6.20 Mar 21, 2017: Retractable Technologies Announces Litigation Updates 69

6.21 Mar 13, 2017: Cancer Genetics to Present at "A Future Without Cancer Conference" on Friday, March 17 69

6.22 Mar 07, 2017: MEDITE Cancer Diagnostics Appoints Eric M. Goehausen to Board of Directors 69

6.23 Mar 01, 2017: Genomic Vision: 2016 Annual Results 70

6.24 Feb 27, 2017: Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre 73

6.25 Feb 23, 2017: MDxHealth Reports Financial Year 2016 Results 73

6.26 Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter 76

6.27 Jan 26, 2017: Quest Diagnostics Reports Fourth Quarter And Full Year 2016 Financial Results; Provides Guidance For Full Year 2017 78

6.28 Jan 26, 2017: Quest Diagnostics Partners With Montefiore Health System to Deliver High-Value, Innovative Laboratory Services 79

6.29 Jan 09, 2017: MDxHealth Announces Preliminary Update on 2016 Results and Appointment of CFO 79

6.30 Jan 09, 2017: Genomic Vision Doubles Its Installed Base of FiberVision Platforms and Quadruples Its Sales of Products and Services in 2016 80

6.31 Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 80

6.32 Dec 20, 2016: Singulex Opens European Office and Advances IVD System Evaluation 81

6.33 Dec 16, 2016: MDxHealth Receives ISO 13485:2016 Certification for Dutch Laboratory 82

6.34 Dec 15, 2016: Quest Diagnostics Board of Directors Elects Stephen H. Rusckowski Chairman of the Board 83

6.35 Nov 11, 2016: Quest Diagnostics Raises Revenue Growth Outlook, Increases Dividend at 2016 Investor Day 83

6.36 Nov 10, 2016: Cancer Genetics Announces Strong Third Quarter with 68% Year over Year Revenue Growth and Highlights Path to Future Profitability 84

6.37 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance 86

6.38 Nov 02, 2016: MDxHealth Provides Third Quarter 2016 Business Update 88

6.39 Oct 20, 2016: Quest Diagnostics Reports Third Quarter 2016 Financial Results 89

6.40 Sep 22, 2016: MDxHealth Announces Upgraded Revenue Forecast 91

6.41 Sep 20, 2016: Early Detection of Ervical cancer: " GynTect 2.0"- Wider Range of Application by Using a Greater Variety of Patient Samples 91

6.42 Aug 24, 2016: bioAffinity Awarded New Patent; Companys Patent Portfolio Continues to Expand 92

6.43 Aug 18, 2016: MDxHealth Reports Second Quarter and First Half 2016 Results 93

6.44 Aug 09, 2016: Cancer Genetics Reports Second Quarter 2016 Financial Results and Provides Company Updates 95

6.45 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter 96

7 Appendix 99

7.1 Methodology 99

7.2 About GlobalData 102

7.3 Contact Us 102

7.4 Disclaimer 102

1.2 List of Figures

Figure 1: Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 9

Figure 2: Cervical Cancer Diagnostic Tests-Pipeline Products by Territory 10

Figure 3: Cervical Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 11

Figure 4: Cervical Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 12

Figure 5: Cervical Cancer Diagnostic Tests-Ongoing Clinical Trials 13

1.1 List of Tables

Table 1: Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 9

Table 2: Cervical Cancer Diagnostic Tests-Pipeline Products by Territory 10

Table 3: Cervical Cancer Diagnostic Tests-Pipeline Products by Regulatory Path 11

Table 4: Cervical Cancer Diagnostic Tests-Pipeline Products by Estimated Approval Date 12

Table 5: Cervical Cancer Diagnostic Tests-Ongoing Clinical Trials 13

Table 6: Cervical Cancer Diagnostic Tests Companies-Pipeline Products by Stage of Development 14

Table 7: Cervical Cancer Diagnostic Tests-Pipeline Products by Stage of Development 16

Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 17

Table 9: NMP179 Test-Product Status 17

Table 10: NMP179 Test-Product Description 17

Table 11: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 18

Table 12: BD SurePath Plus Molecular Pap Test System-Product Status 18

Table 13: BD SurePath Plus Molecular Pap Test System-Product Description 18

Table 14: Biomarker Test-Cervical Cancer-Product Status 19

Table 15: Biomarker Test-Cervical Cancer-Product Description 19

Table 16: Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview 20

Table 17: RNAscope HPV Assay-Cervical Cancer-Product Status 20

Table 18: RNAscope HPV Assay-Cervical Cancer-Product Description 20

Table 19: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 21

Table 20: CyPath Diagnostic Assay-Cervical Cancer-Product Status 21

Table 21: CyPath Diagnostic Assay-Cervical Cancer-Product Description 21

Table 22: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 22

Table 23: Metabolomics-based Diagnostic Assay-Cervical Cancer-Product Status 22

Table 24: Metabolomics-based Diagnostic Assay-Cervical Cancer-Product Description 22

Table 25: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 23

Table 26: Biomarker Assay-Cervical Cancer-Product Status 23

Table 27: Biomarker Assay-Cervical Cancer-Product Description 23

Table 28: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 24

Table 29: Xpert Molecular PAP Assay-Product Status 24

Table 30: Xpert Molecular PAP Assay-Product Description 24

Table 31: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 25

Table 32: Diagnostic Kit-Carcinoma Cervix-Product Status 25

Table 33: Diagnostic Kit-Carcinoma Cervix-Product Description 25

Table 34: Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview 26

Table 35: Laboratory-Based Diagnostic Test-Cervical Cancer-Product Status 26

Table 36: Laboratory-Based Diagnostic Test-Cervical Cancer-Product Description 26

Table 37: Enzo Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Table 38: Next-Generation Branched DNA Assay-Cervical Cancer-Product Status 27

Table 39: Next-Generation Branched DNA Assay-Cervical Cancer-Product Description 27

Table 40: Genisphere LLC Pipeline Products & Ongoing Clinical Trials Overview 28

Table 41: miRNA Biomarker Diagnostic Test-Cervical Cancer-Product Status 28

Table 42: miRNA Biomarker Diagnostic Test-Cervical Cancer-Product Description 28

Table 43: Genomic Vision Pipeline Products & Ongoing Clinical Trials Overview 29

Table 44: HPV Combing Test-Product Status 29

Table 45: HPV Combing Test-Product Description 29

Table 46: Genomic Vision-Ongoing Clinical Trials Overview 30

Table 47: HPV Combing Test-Association Between High-risk HPV Genome Integration Detected by Molecular Combing and Cervical Lesions Severity and/or Evolution 31

Table 48: HPV Combing Test-Integration of Oncogenic HPV DNA in Czech Republic 31

Table 49: GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Table 50: EarlyTect Cervical Cancer-Product Status 32

Table 51: EarlyTect Cervical Cancer-Product Description 32

Table 52: Screening Test-Cervical Cancer-Product Status 33

Table 53: Screening Test-Cervical Cancer-Product Description 33

Table 54: Golden Valley Development, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34

Table 55: XytoTest-Product Status 34

Table 56: XytoTest-Product Description 34

Table 57: GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35

Table 58: Serum-Based Test-Cervical Cancer-Product Status 35

Table 59: Serum-Based Test-Cervical Cancer-Product Description 35

Table 60: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 36

Table 61: Cervical Cancer Remission pT Test-Product Status 36

Table 62: Cervical Cancer Remission pT Test-Product Description 36

Table 63: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 37

Table 64: Diagnostic Test-Cervical Cancer-Product Status 37

Table 65: Diagnostic Test-Cervical Cancer-Product Description 37

Table 66: MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 38

Table 67: ClinicalMDx-Cervical Cancer-Product Status 38

Table 68: ClinicalMDx-Cervical Cancer-Product Description 38

Table 69: Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 39

Table 70: Immunoassay-Cervical Cancer-Product Status 39

Table 71: Immunoassay-Cervical Cancer-Product Description 39

Table 72: Newcastle University Pipeline Products & Ongoing Clinical Trials Overview 40

Table 73: SmartHEALTH POC System-Cervical Cancer-Product Status 40

Table 74: SmartHEALTH POC System-Cervical Cancer-Product Description 40

Table 75: Olympia Diagnostics, Inc Pipeline Products & Ongoing Clinical Trials Overview 41

Table 76: Diagnostic Test-Cervical Cancer-Product Status 41

Table 77: Diagnostic Test-Cervical Cancer-Product Description 41

Table 78: Prognostic Test-Cervical Cancer-Product Status 42

Table 79: Prognostic Test-Cervical Cancer-Product Description 42

Table 80: Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 43

Table 81: GynTect-Product Status 43

Table 82: GynTect-Product Description 43

Table 83: GynTect 2.0-Product Status 44

Table 84: GynTect 2.0-Product Description 44

Table 85: ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 45

Table 86: HPV Companion Diagnostic Test-Cervical Cancer-Product Status 45

Table 87: HPV Companion Diagnostic Test-Cervical Cancer-Product Description 45

Table 88: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 46

Table 89: Diagnostic Assay-Cervical Cancer-Product Status 46

Table 90: Diagnostic Assay-Cervical Cancer-Product Description 46

Table 91: Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 47

Table 92: Diagnostic Assay-Cervical Cancer-Product Status 47

Table 93: Diagnostic Assay-Cervical Cancer-Product Description 47

Table 94: Preciva Incorporated Pipeline Products & Ongoing Clinical Trials Overview 48

Table 95: mColposcope-Product Status 48

Table 96: mColposcope-Product Description 48

Table 97: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 49

Table 98: CINtec Plus Cytology Kit-Product Status 49

Table 99: CINtec Plus Cytology Kit-Product Description 49

Table 100: University of Manchester Pipeline Products & Ongoing Clinical Trials Overview 50

Table 101: Diagnostic Test-Cervical Cancer-Product Status 50

Table 102: Diagnostic Test-Cervical Cancer-Product Description 50

Table 103: US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 51

Table 104: Blood-Based Biomarker-Cervical Cancer-Product Status 51

Table 105: Blood-Based Biomarker-Cervical Cancer-Product Description 51

Table 106: Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 52

Table 107: Companion Diagnostic Assay-Cervical Cancer-Product Status 52

Table 108: Companion Diagnostic Assay-Cervical Cancer-Product Description 52

Table 109: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 53

Table 110: SCCA-IgM Kit-Cervical Cancer-Product Status 53

Table 111: SCCA-IgM Kit-Cervical Cancer-Product Description 53

Table 112: Glossary 101

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alere Inc

Becton Dickinson and Co

Bio Techne Corp

BioAffinity Technologies, Inc.

BioMark Diagnostics Inc.

BioMark Technologies Inc

Cepheid

China Sky One Medical Inc

Cytosystems Ltd

Enzo Life Sciences Inc

Genisphere LLC

Genomic Vision

GenomicTree Inc

Golden Valley Development, Inc.

GRANT Life Sciences, Inc.

Louisville Bioscience, Inc.

MDNA Life Sciences Inc

MDxHealth SA

Milagen Inc

Newcastle University

Olympia Diagnostics, Inc

Oncgnostics GmbH

ONCOVEDA Cancer Research Center

Orion Genomics LLC

Precision Biologics Inc

Preciva Incorporated

Roche Diagnostics International Ltd

University of Manchester

US Biomarkers Inc

Vanderbilt University

XEPTAGEN SpA

Alere Inc, NMP179 Test; Becton Dickinson and Co, BD SurePath Plus Molecular Pap Test System; Becton Dickinson and Co, Biomarker Test-Cervical Cancer; Bio Techne Corp, RNAscope HPV Assay-Cervical Cancer; BioAffinity Technologies, Inc., CyPath Diagnostic Assay-Cervical Cancer; BioMark Diagnostics Inc., Metabolomics-based Diagnostic Assay-Cervical Cancer; BioMark Technologies Inc, Biomarker Assay-Cervical Cancer; Cepheid, Xpert Molecular PAP Assay; China Sky One Medical Inc, Diagnostic Kit-Carcinoma Cervix; Cytosystems Ltd, Laboratory-Based Diagnostic Test-Cervical Cancer; Enzo Life Sciences Inc, Next-Generation Branched DNA Assay-Cervical Cancer; Genisphere LLC, miRNA Biomarker Diagnostic Test-Cervical Cancer; Genomic Vision, HPV Combing Test; GenomicTree Inc, EarlyTect Cervical Cancer; GenomicTree Inc, Screening Test-Cervical Cancer; Golden Valley Development, Inc., XytoTest; GRANT Life Sciences, Inc., Serum-Based Test-Cervical Cancer; Louisville Bioscience, Inc., Cervical Cancer Remission pT Test; MDNA Life Sciences Inc, Diagnostic Test-Cervical Cancer; MDxHealth SA, ClinicalMDx-Cervical Cancer; Milagen Inc, Immunoassay-Cervical Cancer; Newcastle University, SmartHEALTH POC System-Cervical Cancer; Olympia Diagnostics, Inc, Diagnostic Test-Cervical Cancer; Olympia Diagnostics, Inc, Prognostic Test-Cervical Cancer; Oncgnostics GmbH, GynTect; Oncgnostics GmbH, GynTect 2.0; ONCOVEDA Cancer Research Center, HPV Companion Diagnostic Test-Cervical Cancer; Orion Genomics LLC, Diagnostic Assay-Cervical Cancer; Precision Biologics Inc, Diagnostic Assay-Cervical Cancer; Preciva Incorporated, mColposcope; Roche Diagnostics International Ltd, CINtec Plus Cytology Kit; University of Manchester, Diagnostic Test-Cervical Cancer; US Biomarkers Inc, Blood-Based Biomarker-Cervical Cancer; Vanderbilt University, Companion Diagnostic Assay-Cervical Cancer; XEPTAGEN SpA, SCCA-IgM Kit-Cervical Cancer

select a license

Single User License
USD 4000 INR 269800
Site License
USD 8000 INR 539600
Corporate User License
USD 12000 INR 809400

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com